Search Results

You are looking at 1 - 10 of 15 items for :

  • Refine by Access: All content x
Clear All
Open access

Akihiko Ando, Shoichiro Nagasaka, and Shun Ishibashi

genetic testing was performed on her two children and the other family members. Treatment Oral hypoglycemic agent gliclazide at 20 mg was added to the intensive insulin therapy (31 U insulin lispro and 14 U insulin degludec per day). The gliclazide

Open access

E Rapti, S Karras, M Grammatiki, A Mousiolis, X Tsekmekidou, E Potolidis, P Zebekakis, M Daniilidis, and K Kotsa

patient declined insulin therapy and was initially treated with gliclazide once daily and metformin 1000mg twice daily with the suggestion of regular consultation in an outpatient diabetes clinic. On presentation to the diabetes outpatient setting 3

Open access

Aoife Garrahy, Matilde Bettina Mijares Zamuner, and Maria M Byrne

-referred to the diabetic services. Ketones were negative and she had no osmotic symptoms. She was commenced initially on gliclazide 60 mg and metformin 500 mg twice daily. Mixed insulin was added at 4 months due to osmotic symptoms and HbA1C of 93 mmol/mol (10

Open access

N Siddique, R Durcan, S Smyth, T Kyaw Tun, S Sreenan, and J H McDermott

diagnosis of DM. Basal-bolus insulin was instituted and resulted in resolution of hyperglycaemia and osmotic symptoms. Insulin was subsequently discontinued, and he was discharged on metformin 1000 mg twice a day and gliclazide modified release of 30 mg a

Open access

Khaled Aljenaee, Osamah Hakami, Colin Davenport, Gemma Farrell, Tommy Kyaw Tun, Agnieszka Pazderska, Niamh Phelan, Marie-Louise Healy, Seamus Sreenan, and John H McDermott

mellitus (T2DM) made 2 years previously. His diabetes regimen included metformin, gliclazide and dapagliflozin. His daughter had a history of type 1 diabetes mellitus (T1DM), and he himself had coeliac disease with associated dermatitis herpetiformis, for

Open access

Michal Barabas, Isabel Huang-Doran, Debbie Pitfield, Hazel Philips, Manoj Goonewardene, Ruth T Casey, and Benjamin G Challis

hypoglycaemic agent (40 mg gliclazide once daily). The patient reported pre-existing hypertension and osteoporosis. Notably, she had been investigated 4 years ago for left ventricular impairment of unknown aetiology. There was no history of venous thromboembolic

Open access

Mohammed Faraz Rafey, Arslan Butt, Barry Coffey, Lisa Reddington, Aiden Devitt, David Lappin, and Francis M Finucane

hypoglycaemia. His insulin was stopped and gliclazide MR 30 mg was started, with subsequent excellent glycaemic control. However, over the following 18 months he required an increased dose of gliclazide MR to 120 mg daily and the introduction of sitagliptin 100

Open access

Diana Catarino, Cristina Ribeiro, Leonor Gomes, and Isabel Paiva

had been diagnosed with diabetes mellitus for 1 year (since January 2017). At the time of diagnosis, the A1C was 10.8% and she was prescribed metformin (850 mg, twice daily) and gliclazide (60 mg, once daily). She was also diagnosed with arterial

Open access

Mimi Wong, Usman H Malabu, Ipeson Korah, and YongMong Tan

her compassionate supply of pasireotide. While on the lower pasireotide dose her diabetes was well controlled on metformin 2 g daily and with the subsequent addition of gliclazide modified release (MR) 30 mg daily ( Fig. 3 ). Her HbA1c was 6.8% after

Open access

Ziadoon Faisal and Miguel Debono

, gliclazide, metformin, bisoprolol and sublingual glyceryl trinitrate. On examination, his temperature was 36.8°C, BP 178/115 mmHg, pulse rate 122 bpm, weight 89.6Kg and BMI 28.2kg/m 2 . The patient had Cushingoid features, including a round face